Johnson & Johnson's earnings call revealed ongoing challenges, including sales declines from OTC product recalls, pricing pressures, and impacts from U.S. healthcare reforms and European austerity measures. Management provided cautious guidance for 2011, highlighting continued pricing pressures and lower-than-expected sales growth. This outlook may lead to short-term negative sentiment among investors, likely causing the stock price to decline in the next 1â€“2 weeks.

[-1]